Contract Research Organizations (CRO) Sector Outlook — September 2026
A September 2026 sector outlook on Contract Research Organizations, covering eleven public companies' forward revenue valuations, nine precedent transactions with disclosed terms, and what the two-price-band pattern means for owners, buyers and boards.
For information only. Not an appraisal or a fairness opinion.
What moved since: Contract Research Organizations (CRO) M&A update, 14–28 September 2026
Key figures
- Sector median valuation
- 3.1x
- EV/Revenue, CY2027E consensus
- Top of forward range
- 11.1x
- EV/Revenue, CY2027E, highest-priced name
- Bottom of forward range
- 0.8x
- EV/Revenue, CY2027E, lowest-priced name
- Sponsor-side share of set
- 73%
- 8 of 11 companies
Read the report
1 / 21 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO)
Executive summary
Contract Research Organizations in this set price as two businesses on the same forward revenue lens: platform and franchise economics at the top of the range, and service-capacity names carrying funding-cycle exposure at the bottom. The sector median sits at 3.1x forward revenue, spanning from 0.8x to 11.1x across nine rated companies. Precedent transactions show buyers paying separately for backlog, capacity and therapeutic depth on a profit-multiple basis. Revenue quality is the lever this data puts in an owner's hands.
Key findings
- CRO valuations split into two price bands on the same forward revenue lens.
- Sponsor-side platform names make up 73% of the set, yet price at 2.1x.
- Faster-growing names trade at 1.0x; slower growers command 3.8x forward revenue.
- Precedent deals price on profit multiples of 11.7x to 24.4x, not revenue.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO)
This is the cover page identifying the report as NeuraCap's September 2026 Contract Research Organizations sector outlook.
We built this report to show how the contract research organization sector prices today, using market data as of September 28, 2026. What follows walks through the valuation split, the transaction record and what it means for owners and buyers.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CONTRACT RESEARCH ORGANIZATIONS (CRO) Contract Research: Two Price Bands, One Sector Label This report shows how the companies in this sector are valued on a forward revenue lens, what the transaction record contains, and where each group sits. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This slide lists the report's five sections plus the appendix, covering the bottom line, market landscape, valuation, precedent transactions and strategic implications.
We've structured this report so the bottom line comes first — if you only have five minutes, section one gives you the whole story. From there we build the case with the market map, the valuation detail, the transaction record and what each finding means for owners and buyers. That order means every additional page adds depth rather than a new conclusion, so you can stop wherever your time runs out.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Contract Research Organizations Split into Two Pricing Worlds 02 The Landscape Most of the Names Are Sponsor-Side; The Service Economics Sit in Two 03 Valuation & Situations The Forward Revenue Lens Puts Real Distance Between the Two Ends 04 Precedent Transactions Buyers Agreed to Pay up for Backlog, Capacity and Therapeutic Depth 05 Strategic Implications Revenue Quality Is What an Owner Can Move, and It Tracks with the Valuation Range 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Contract Research Organizations Price as Two Businesses: Service Capacity and Partnership Platforms
This slide states the report's central finding: Contract Research Organizations price as two distinct businesses — service capacity and partnership platforms.
We find that contract research organizations in this set price as two businesses, not one, on the same forward revenue lens. The median across nine rated names sits at 3.1x forward revenue, with the top of the range at 11.1x and the bottom at 0.8x. We lead with revenue because only three of the eleven companies carry a meaningful forward EBITDA estimate. That spread is the single fact every other page in this report explains.
Everything on this page
01 · THE BOTTOM LINE Contract Research Organizations Price as Two Businesses: Service Capacity and Partnership Platforms The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Distance Between the Two Price Bands Is Worth Managing To Across the 9 names with a forward estimate, the middle of the range sits at 3.1x forward revenue for CY2027E. The top band prices at 11.1x and the bottom band at 0.8x. Revenue is the lead measure here because forward profit estimates are reported for 3 of the 11 companies. 2 Most of the Set Is Sponsor-Side Platform Economics 8 of the 11 companies are classified as sponsor-side therapeutic drug developers, 73% of the set, and the middle of that group prices at 2.1x forward revenue. Only two names sit in research models and safety assessment, where billable capacity, utilisation and backlog conversion do the work. 3 Faster Growth Is Not Where the Higher Multiples Sit Today On the 9 names with a forward estimate, the 5 growing faster than 9% sit at 1.0x forward revenue and the 4 growing slower sit at 3.8x. A forward lens already credits the growth in the forecast, so the higher prices are sitting alongside established franchise and platform economics rather than the fastest top-line runners. 4 What Buyers Agreed to Pay for Whole Companies Is the Second Benchmark Across the 9 transactions in this record, announced profit multiples run from 11.7x to 24.4x EBITDA, with private-equity and strategic buyers at both ends. Diligence in this market centres on backlog quality: contracted versus awarded work, cancellation terms and conversion history. 3.1x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because only 3 of 11 names carry a meaningful forward EBITDA 11.1x Premium end EV/Revenue vs 0.8x at the discount end top quartile (n=2) against bottom quartile (n=3) on EV/Revenue — the spread the report explains 13 Transactions with disclosed terms 35 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces section two, covering the market map across three business groups and eleven companies.
This section maps the eleven companies in our set into three business groups, each selling to a different buyer. Understanding who buys from whom is the foundation for reading the valuation gap we walk through next.
Everything on this page
SECTION 02 02 THE LANDSCAPE Most of the Names Are Sponsor-Side; The Service Economics Sit in Two Three groups, 11 companies, and different buyer groups behind each of them. 02 of 06 Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Three Groups Under One Label, Selling to Different Buyer Groups
This slide groups the eleven approved companies into three business segments and shows each group's median EV/Revenue for CY2027E.
We've sorted the eleven-company universe into three groups — sponsor-side platforms, research and safety assessment, and manufacturing — because each sells to a different buyer and prices differently as a result. Grouping by segment rather than by size or geography is what makes the valuation gap in this report explainable rather than just observed. That structure is what the next page builds on.
Everything on this page
02 · MARKET MAP Three Groups Under One Label, Selling to Different Buyer Groups 11 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: THERAPEUTIC DRUG DEVELOPERS (SPONSOR-SIDE) 8 cos median 2.1x AbCellera (ABCL) Fortrea Holdings (FTRE) OmniAb (OABI) Aclaris (ACRS) C4 Therapeutics (CCCC) Cellectis S.A. (CLLS) Champions Oncology (CSBR) MindWalk Holdings (HYFT) The largest group by count, priced at 2.1x forward revenue in the middle, where value is discussed in partnered programmes and downstream economics rather than billable hours. RESEARCH MODELS AND SAFETY ASSESSMENT 2 cos median 3.8x IQVIA Holdings (IQV) Charles River (CRL) Two names carrying the scaled service economics of this market: physical capacity, utilisation, backlog conversion and long-dated sponsor relationships. ADJACENT: SPECIALTY AND GENERIC DRUG MANUFACTURING 1 cos 0.6x · 1 rated Evotec SE (EVO) A single name, Evotec SE (EVO), at 0.6x forward revenue, where manufacturing economics sit alongside discovery service work.
- 0602 · LANDSCAPE
Platform Economics, Service Capacity and Manufacturing Sit Side by Side Here
This slide lays out what each segment does and why it matters, placing platform economics, service capacity and manufacturing side by side.
Here we set platform economics, service capacity and manufacturing side by side so you can see what each business model actually sells before we get to price. The three groups look similar from the outside — all labeled CRO — but the underlying economics driving their valuations are different. Full company-level detail sits in the appendix if you want to trace any single name.
Everything on this page
02 · LANDSCAPE Platform Economics, Service Capacity and Manufacturing Sit Side by Side Here Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Adjacent: therapeutic drug developers (sponsor-side) 8 73% 2.1x AbCellera Biologics Inc. (ABCL) · Fortrea Holdings Inc. (FTRE) · +6 more Platform economics, sponsor-side. 8 of the 11 companies sit here, 73% of the set. Value in this group is discussed in terms of partnered-programme progression, milestone and royalty participation, and the funding environment behind emerging-biotech demand, rather than billable headcount and utilisation. Research models and safety assessment 2 18% 3.8x IQVIA Holdings Inc. (IQV) · Charles River Laboratories International, Inc. (CRL) Capacity, utilisation and backlog. Two names, 18% of the set: IQVIA Holdings Inc. (IQV) and Charles River Laboratories International, Inc. (CRL). Both carry the profitability of scaled service operations, at margins of 23% and 25% respectively, and both live on net new business awards, book-to-bill and backlog burn. Adjacent: specialty and generic drug manufacturing 1 9% 0.6x n=1 Evotec SE (EVO) One name, manufacturing-led. Evotec SE (EVO) is the single company classified here, priced at 0.6x forward revenue, at the bottom of this set's range. Its economics blend discovery service work with manufacturing capacity, and that mix is read differently from a pure services book.
- 07SECTION 03
03
This divider introduces section three, the public market valuation analysis on a forward revenue basis.
This section puts the forward revenue lens to work across all eleven companies, nine of which carry a forward estimate. It's where the two-price-band finding gets its numbers.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Forward Revenue Lens Puts Real Distance Between the Two Ends All 11 companies appear; 9 of them carry a forward estimate. 03 of 06 Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
Two Names Hold the Top of the Forward Revenue Range; Three Hold the Bottom
This slide ranks the nine rated companies by EV/Revenue for CY2027E and shows where the top and bottom of the range sit against the sector median.
Ranking the nine rated names by forward revenue multiple shows two names holding the top of the range and three holding the bottom, against a sector median of 3.1x. We use EV/Revenue here because only three of the eleven companies carry a meaningful forward EBITDA estimate, so revenue is the measure that lets us compare the whole set on one basis. The distance between the top and bottom of this range is the gap an owner or buyer needs to understand before pricing any conversation.
Everything on this page
03 · PUBLIC MARKET VALUATION Two Names Hold the Top of the Forward Revenue Range; Three Hold the Bottom EV / Revenue (CY2027E) · all 9 rated companies, sorted descending · sector median 3.1x · EV/Revenue is the lens because only 3 of 11 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 11.1x CORE · median 3.2x DISCOUNT · median 0.8x Sector median 3.1x WHAT SEPARATES THE TWO ENDS The top band prices at 11.1x. The two names at the top of the forward revenue range for CY2027E sit there on a lens that already credits forecast growth. A price that survives that test points to something the market is treating as durable: partnership participation rather than project-by-project flow. The bottom band sits at 0.8x. Three names sit at the bottom of the same forward measure. In this set that band is occupied by companies with concentrated sponsor exposure, exposure to the emerging-biotech funding cycle and fixed capacity to fill — the features buyers test hardest in diligence. Two names carry no estimate. 9 of the 11 companies carry a forward estimate. AbCellera Biologics Inc. (ABCL) and Aclaris Therapeutics, Inc. (ACRS) do not, so the range describes the market's view of 9 names rather than the full set of 11.
- 0903 · VALUATION DRIVERS
The Higher Multiples Sit with the Slower Growers in This Set
This slide splits the rated companies into faster- and slower-growth cohorts and shows the higher median multiple sits with the slower growers.
When we split the rated set into faster and slower revenue-growth cohorts, the slower growers carry the higher median multiple at 3.8x versus 1.0x for the faster growers. That pattern is an association in this data, not a claim that slower growth causes a higher price — a forward lens already credits expected growth, so a higher price today reflects something else, most likely franchise and platform durability. That distinction matters for how a growing company should expect to be read by this market.
Everything on this page
03 · VALUATION DRIVERS The Higher Multiples Sit with the Slower Growers in This Set Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=5; slower n=4; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 9% · EBITDA-margin split at n/a Above 9% Growth, the Set Prices at 1.0x Splitting the 9 names with a forward estimate at 9% revenue growth, the 5 faster names sit at 1.0x forward revenue and the 4 slower names sit at 3.8x. That is what this sample shows as of 2026-09-28; it is not evidence that slower growth is worth more. Backlog Conversion Is Where Awards Become Revenue Award growth and revenue growth run on different clocks here: net new business awards land quarters before they burn into revenue, and cancellations are a structural feature of the book. A growth rate on its own does not tell a buyer whether the backlog is converting. The Top Band Sits Alongside Partnered-Programme Economics The two names at the top of the forward range are platform businesses whose value is discussed in partnered programmes, milestones and downstream royalties. That is what the top band sits alongside in this set; the record shows the prices, not the reasoning behind them.
- 1003 · SITUATION MAP
Only 2 of the 9 Names with a Forward Estimate Price High and Grow Fast
This slide cuts the nine rated companies on valuation versus the sector median and growth versus the covered median, showing only two names price high and grow fast.
Cutting the nine-name set on price against the median and growth against the median leaves only two companies in the high-price, fast-growth quadrant. Most of the set sits somewhere else — priced for franchise durability without fast growth, or growing without a premium multiple yet attached. These are observations about where each company sits today, not calls to buy or sell any of them.
Everything on this page
03 · SITUATION MAP Only 2 of the 9 Names with a Forward Estimate Price High and Grow Fast Cut on EV / Revenue vs the sector median (3.1x) (rows) and revenue growth vs the covered median (9%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced High, Growing Fast Above-median multiple · above-median revenue growth 2 names OmniAb, Inc. (OABI) · MindWalk Holdings Corp. (HYFT) OmniAb, Inc. (OABI) at 15.1x and MindWalk Holdings Corp. (HYFT) sit above the middle of the set on both price and growth. The live question for an owner in this position is conversion: whether award and partnership momentum keeps turning into revenue at the same rate. Priced High, Growing Slowly Above-median multiple · below-median revenue growth 3 names IQVIA Holdings Inc. (IQV) · Charles River Laboratories International, Inc. (CRL) · C4 Therapeutics, Inc. (CCCC) IQVIA Holdings Inc. (IQV), Charles River Laboratories International, Inc. (CRL) and C4 Therapeutics, Inc. (CCCC) price above the middle while growing below it. In this set that position is associated with established franchises and long-dated books rather than near-term top-line speed. Growing Fast, Priced Low Below-median multiple · above-median revenue growth 3 names Evotec SE (EVO) · Cellectis S.A. (CLLS) · Champions Oncology, Inc. (CSBR) Evotec SE (EVO), Cellectis S.A. (CLLS) and Champions Oncology, Inc. (CSBR) grow faster than the middle of the set but price below it. Cellectis S.A. (CLLS) grows at 72% and still sits in the bottom band, which puts the durability and mix of that revenue ahead of its rate as the question. Below the Middle on Both Below-median multiple · below-median revenue growth 1 names Fortrea Holdings Inc. (FTRE) Fortrea Holdings Inc. (FTRE) is the single name below the middle on both measures, at 1.1x forward revenue. The operating focus in that position is the quality of the book: cancellation rates, award conversion and sponsor concentration.
- 1103 · THE AGENDA
Different Revenue Models Sit at Different Prices in the Transaction Record
This slide frames the questions an owner or acquirer should resolve given how different revenue models price in the transaction record.
Different revenue models in this set clear at different prices in the transaction record, and that's the agenda item every owner in this space should put on the table. The questions aren't about whether the business is good — they're about which revenue model it's being read as today. We turn to the transaction record itself next.
Everything on this page
03 · THE AGENDA Different Revenue Models Sit at Different Prices in the Transaction Record NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Build the Backlog a Buyer Can Underwrite Value in scaled service economics is discussed in contracted versus awarded work, conversion history and cancellation terms. Concentrating commercial effort on longer-dated, preferred-provider work changes the shape of the book that buyers and public investors read. What changes the answer: A run of quarters where net new business awards convert into revenue on schedule. Choose How Much Platform Economics to Carry This set contains businesses paid for billable capacity and businesses paid for partnered-programme participation, and several carry both inside one P&L. Deciding which of the two the company is building shapes pricing, capital allocation and which buyer group engages. What changes the answer: Milestone and royalty income becoming a repeatable share of revenue rather than a lumpy line. Spread Sponsor Exposure Across the Two Demand Cycles Emerging-biotech demand moves with the funding environment; large-pharma demand moves with portfolio and patent timing. A book weighted to one of those cycles carries a different risk profile from one that holds both, and diligence tests that concentration directly. What changes the answer: A meaningful shift in the share of revenue coming from the top handful of sponsors. Settle Build Versus Buy on Capacity and Data Preclinical capacity, therapeutic-area depth and site and patient data assets are the features strategic acquirers in this record moved to add. Those same features can be built, and choosing between building and acquiring them is a capital allocation decision. What changes the answer: Utilisation running at the limits of current capacity.
- 12SECTION 04
04
This divider introduces section four, nine announced precedent transactions between 2013 and 2023 with disclosed terms.
This section walks through what buyers actually paid — transactions with disclosed terms, spanning strategic and private-equity buyers on both sides between 2013 and 2023. It's the second benchmark alongside the trading multiples we just covered.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Agreed to Pay up for Backlog, Capacity and Therapeutic Depth Nine announced transactions between 2013 and 2023, strategic and private-equity buyers on both sides. 04 of 06 Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Strategics and Private Equity Both Agreed to Pay up, 2013 to 2023
This slide presents one of the disclosed-terms transactions as a case study, with multiples on LTM financials at announcement.
We walk through this transaction as a case study because it shows what buyers were willing to pay for backlog, capacity and therapeutic depth, on the LTM-at-announcement basis. Deal multiples here aren't directly comparable to the CY2027E trading basis we used earlier — different measurement, different point in time — so we don't draw a spread between them. The complete list of disclosed-terms transactions sits in the appendix for anyone who wants the full record.
Everything on this page
04 · DEAL CASE STUDIES Strategics and Private Equity Both Agreed to Pay up, 2013 to 2023 1 of 13 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 36 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 22 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Nov-2023 $3.1B Light Curve Capital Holdings Pte. Ltd (subsidiary) acquires Alvotech Hannover GmbH EV / LTM revenue 50.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The buyer is a capital holding vehicle and the target is a manufacturing operation, which suggests an asset-and-capacity transaction rather than a services consolidation. What the transaction suggests is appetite for qualified production capability of a kind that takes years to build. HOW THE TARGET WAS VALUED The announced value is $3.1B and the record carries 50.9x revenue against it, with the filing's value unit unresolved, so the multiple should be read as indicative. It sits outside the profit multiples recorded for the clinical services transactions here, a reminder that a manufacturing asset and a services book are not benchmarked the same way.
- 14SECTION 05
05
This divider introduces section five, the strategic implications for owners, buyers and boards.
This section turns the valuation and transaction evidence into what it means for owners, buyers and boards over the next twelve months. Revenue quality is the thread that connects everything we've shown so far.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Revenue Quality Is What an Owner Can Move, and It Tracks with the Valuation Range What the evidence points to for owners, buyers and boards. 05 of 06 Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Revenue Quality Is the Lever This Data Puts in an Owner's Hands
This slide sets out the questions the data puts on the table for owners, buyers and boards over the next twelve months.
Revenue quality is the lever this data puts directly in an owner's hands — it's the one variable inside a company's control that lines up with where names sit in the valuation range. For buyers, bridging the revenue and profit-multiple benchmarks starts with agreeing net revenue before pass-through costs. For boards, backlog conversion and sponsor concentration are the same features this report shows the market pricing already. These are the practical next steps this analysis supports.
Everything on this page
05 · STRATEGIC IMPLICATIONS Revenue Quality Is the Lever This Data Puts in an Owner's Hands NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Mix Is the Lever with the Clearest Read In this set the higher forward prices sit with platform and established franchise economics, and the lower prices sit with names carrying funding-cycle exposure and fixed capacity. Shifting mix toward contracted, longer-dated and partnered revenue is an operating decision that changes how the business reads against these peers. FOR BUYERS The Two Benchmarks Are Priced on Different Measures Announced transactions in this record are discussed in profit multiples, while the trading set is read on forward revenue because forward profit estimates are reported for 3 of the 11 companies. Bridging the two means agreeing net revenue before pass-through and reimbursed costs, usually the first substantive negotiation in a process. FOR BOARDS Backlog Quality Is Associated with Where a Name Sits Across this set, the names at the top of the forward range are the ones with platform participation or long-dated sponsor relationships, and that position is associated with the durability of the book rather than the growth rate reported in any single year. Board attention on conversion, cancellation and sponsor concentration meets the same features buyers test.
- 16SECTION 06
06
This divider introduces the appendix, covering the full comparables universe, precedent transactions and methodology.
This closing section carries the full comparables universe, the complete transaction list, and the methodology behind every figure in this report. It's the reference material for tracing any number back to its source.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This appendix page lists all rated companies on EV/Revenue for CY2027E, grouped by valuation tier against the sector median.
This page carries every rated company in the set, grouped by whether it prices above or below the 3.1x sector median, with tickers linking to the underlying source. A small number of names in the universe carry no eligible multiple and are listed separately in the companion workbook. Use this page to locate any single name inside the valuation story we've just walked through.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.1x); amber marks below · 9 rated companies; 2 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 9 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥4.3x · median 11.1x · 2 companies OmniAb, Inc. OABI Adjacent: therapeutic drug developers (sponsor-side) $657M 15.1x 24% n/a n/a C4 Therapeutics, Inc. CCCC Adjacent: therapeutic drug developers (sponsor-side) $147M 7.2x -20% n/a n/a CORE — 1.0x–4.3x · median 3.2x · 4 companies Charles River Laboratories International, Inc. CRL Research models and safety assessment $17.1B 4.3x 2% 25% n/a IQVIA Holdings Inc. IQV Research models and safety assessment $59.3B 3.2x 6% 23% 29 MindWalk Holdings Corp. HYFT Adjacent: therapeutic drug developers (sponsor-side) $53M 3.1x 27% n/a n/a Fortrea Holdings Inc. FTRE Adjacent: therapeutic drug developers (sponsor-side) $2.9B 1.1x 3% 8% 12 DISCOUNT — <1.0x · median 0.8x · 3 companies Champions Oncology, Inc. CSBR Adjacent: therapeutic drug developers (sponsor-side) $68M 1.0x 9% n/a n/a Cellectis S.A. CLLS Adjacent: therapeutic drug developers (sponsor-side) $72M 0.8x 72% n/a n/a Evotec SE EVO Adjacent: specialty and generic drug manufacturing $499M 0.6x 20% 20% 49
- 1806 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This appendix page lists precedent transactions with disclosed terms, newest first, with multiples on LTM financials at announcement.
This page lists the transactions with disclosed terms in newest-first order, each with deal values linking to the underlying filing. Some records carry data-quality flags, noted where they occur, and are shown as recorded in the filing rather than adjusted. Transactions without a disclosed value or multiple are kept in the companion workbook rather than listed here.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 13 transactions with disclosed terms in this tier (35 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 36 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 22 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Nov-2023 Light Curve Capital Holdings Pte. Ltd (subsidiary) → Alvotech Hannover GmbH $3.1B 50.9x n/a Announced November 2023 with a disclosed value of $3.1B and recorded at 50.9x revenue; the filing's value unit is unresolved, so read the multiple as indicative. The buyer is a capital holding vehicle and the target is a manufacturing operation. Apr-2021 Thermo Fisher Scientific Inc. → PPD, Inc. n/a n/a 23.4x Announced April 2021 at 23.4x EBITDA, toward the top of the profit multiples in this record. A tools and diagnostics group adding full-service clinical development fits the cross-sell logic strategic buyers describe into an existing sponsor base. Feb-2021 ICON plc → PRA Health Sciences, Inc. n/a n/a 24.4x Announced February 2021 at 24.4x EBITDA. Two clinical development providers combining is a recurring structure in this record, adding therapeutic-area depth and geographic reach in a single step. Jul-2017 Laboratory Corporation of America Holdings → Chiltern International Group Limited n/a n/a 12.6x Announced July 2017 at 12.6x EBITDA, toward the lower end of the profit multiples recorded here. Laboratory groups appear twice in this record as buyers of clinical development capability. Jun-2017 Pamplona Capital Management → PAREXEL International Corporation n/a n/a 13.3x Announced June 2017 at 13.3x EBITDA. Sponsors in this market look at contracted backlog and recurring project flow, and assembling functional specialists into a broader platform is a familiar structure for them. Jun-2017 GTCR, LLC, The Carlyle Group L.P. → Albany Molecular Research, Inc. n/a n/a 13.6x Announced June 2017 at 13.6x EBITDA. A club transaction for a discovery and development chemistry business shows sponsor appetite reaching research capacity as well as clinical services. Jun-2016 Quintiles → IMS Health Holdings, Inc. n/a n/a 13.0x Announced June 2016 at 13.0x EBITDA. This is the combination in the record that pairs a health data business with clinical delivery capacity, the asset set strategic buyers say is hard to assemble quickly. Nov-2014 Laboratory Corporation of America Holdings → Covance, Inc. n/a n/a 13.3x Announced November 2014 at 13.3x EBITDA, the same level recorded three years later for PAREXEL International Corporation. Preclinical and safety capacity is hard to add quickly, and this record shows buyers acquiring it rather than building it. Jun-2013 KKR & Co. Inc. → PRA Health Sciences, Inc. n/a n/a 11.7x Announced June 2013 at 11.7x EBITDA, the lowest profit multiple among the 9 transactions in this record. The same target appears again in this record in 2021, that time with a strategic buyer.
- 1906 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This second appendix page continues the newest-first list of precedent transactions with disclosed terms.
This page continues the disclosed-terms transaction list in the same newest-first order, with deal values linking to the underlying filing. As on the prior page, flagged records are shown as recorded rather than adjusted. Together the two pages carry the full set of transactions with disclosed terms in this record.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 13 transactions with disclosed terms in this tier (35 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 36 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 22 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2013 Kohlberg Kravis Roberts → PRA Health Sciences, Inc. n/a n/a 11.7x Jul-2007 Genstar Capital, LLC → PRA International n/a n/a 15.1x n/a n/a → Syneos Health, Inc. n/a 1.8x 14.6x Value shown as recorded in the filing; status defaulted announced. n/a n/a → InVentiv Health, Inc. n/a n/a 10.2x Value shown as recorded in the filing; status defaulted announced.
- 2006 · METHODOLOGY
Sources, Assumptions and Data Quality
This slide documents the sources, assumptions and data-quality treatment behind the report.
Every figure in this report links back to the record it was taken from, and where a link isn't available, the appendix names the source and the basis on which it was read. This is where we document what was excluded and why, so the analysis is transparent to review. Use this page as the reference point for any question about how a specific number was built.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Contract Research Organizations (CRO) and it clears the coverage gate with 11 of 11 companies (100%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because forward EBITDA is reported for 3 of 11 companies. DATA QUALITY & EXCLUSIONS 37 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 481 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (480) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 21
In This Set the Top of the Forward Range Sits with Platform and Franchise Economics.
This closing slide restates the report's finding: the top of the forward range in this set sits with platform and franchise economics.
In this set, the top of the forward range sits with platform and franchise economics, not with the fastest revenue growth. The companion tables alongside this deck carry the full universe, the exclusion ledger and the complete source index for any figure you want to trace further. That's the finding we'd want you to carry into your next conversation about this sector.
Everything on this page
In This Set the Top of the Forward Range Sits with Platform and Franchise Economics. NeuraCap AI — Contract Research Organizations (CRO) Coverage September 2026 · Prepared by NeuraCap AI · Confidential Contract Research Organizations (CRO) Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21
Sources and methodology
This report covers Contract Research Organizations (CRO) (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Contract Research Organizations (CRO)) with market data and consensus estimates as of September 28, 2026. The company universe is the 11 listed companies whose core business is Contract Research Organizations (CRO) according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbCellera Biologics Inc. (ABCL), Aclaris Therapeutics, Inc. (ACRS), C4 Therapeutics, Inc. (CCCC), Cellectis S.A. (CLLS), Charles River Laboratories International, Inc. (CRL), Champions Oncology, Inc. (CSBR), Evotec SE (EVO), Fortrea Holdings Inc. (FTRE), MindWalk Holdings Corp. (HYFT), IQVIA Holdings Inc. (IQV), OmniAb, Inc. (OABI). The market map groups them by business vertical — Adjacent: therapeutic drug developers (sponsor-side): 8 companies (ABCL, FTRE, OABI, ACRS, CCCC, CLLS, CSBR, HYFT); Research models and safety assessment: 2 companies (IQV, CRL); Adjacent: specialty and generic drug manufacturing: 1 company (EVO). 9 of the 11 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Contract Research Organizations (CRO) (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Contract Research Organizations (CRO)) with market data and consensus estimates as of September 28, 2026. The company universe is the 11 listed companies whose core business is Contract Research Organizations (CRO) according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbCellera Biologics Inc. (ABCL), Aclaris Therapeutics, Inc. (ACRS), C4 Therapeutics, Inc. (CCCC), Cellectis S.A. (CLLS), Charles River Laboratories International, Inc. (CRL), Champions Oncology, Inc. (CSBR), Evotec SE (EVO), Fortrea Holdings Inc. (FTRE), MindWalk Holdings Corp. (HYFT), IQVIA Holdings Inc. (IQV), OmniAb, Inc. (OABI). The market map groups them by business vertical — Adjacent: therapeutic drug developers (sponsor-side): 8 companies (ABCL, FTRE, OABI, ACRS, CCCC, CLLS, CSBR, HYFT); Research models and safety assessment: 2 companies (IQV, CRL); Adjacent: specialty and generic drug manufacturing: 1 company (EVO). 9 of the 11 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
37 records failed a validation gate and never feed a statistic in this report (34 excluded from aggregate; 3 quarantined). Each exclusion, with its reason: ABCL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABCL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABCL — Implied EBITDA margin -919.5% outside the plausible band [-100%, 80%] (effect: quarantined) · ABCL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABCL — Implied EBITDA margin -979.8% outside the plausible band [-100%, 80%] (effect: quarantined) · ABCL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABCL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABCL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ABCL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CCCC — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CCCC — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CCCC — Implied EBITDA margin -510.4% outside the plausible band [-100%, 80%] (effect: quarantined) · CCCC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CCCC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CCCC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CCCC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLLS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CRL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSBR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSBR — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EVO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 11 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Contract Research Organizations (CRO) and it clears the coverage gate with 11 of 11 companies (100%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because forward EBITDA is reported for 3 of 11 companies. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 3 of 11 companies; EV / rEVenue: 11 of 11 companies; P/E: 4 of 11 companies. 2 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 4 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥4.3x, Core 1.0x–4.3x, Discount <1.0x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 3.1x = median(ev_revenue CY2027E) (9 rated companies) · 11.1x = median(ev_revenue CY2027E) within Premium tier (n=2) · 3.2x = median(ev_revenue CY2027E) within Core tier (n=4) · 0.8x = median(ev_revenue CY2027E) within Discount tier (n=3) · 1.0x = median(ev_revenue CY2027E) | growth ≥ 9% (n=5) · 3.8x = median(ev_revenue CY2027E) | growth < 9% (n=4) · 28% = median Rule of 40 score (revenue growth + EBITDA margin) (n=4)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Contract Research Organizations (CRO) recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 35 transactions were recorded for this industry; 13 are shown. 22 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 23 × no evidence record; 8 × deal value unit unresolved; 4 × duplicate precedent id; 1 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 485 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- AbCellera (ABCL) (sec.gov)
- Fortrea Holdings (FTRE) (sec.gov)
- OmniAb (OABI) (sec.gov)
- Aclaris (ACRS) (sec.gov)
- C4 Therapeutics (CCCC) (sec.gov)
- Champions Oncology (CSBR) (sec.gov)
- IQVIA Holdings (IQV) (sec.gov)
- Charles River (CRL) (sec.gov)
- $3.1B (sec.gov)
- n/a (sec.gov)
- 23.4x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- sec.gov (480) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Diagnostic and Testing Equipment M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Diagnostic and Testing Equipment Sector Outlook — September 2026
- M&A Update · 29 September 2026Digital Health and Telehealth M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Digital Health and Telehealth Sector Outlook — September 2026
Want this analysis for a company in Contract Research Organizations (CRO)?
Company valuation reports run the same method against a single business — public or private.
